Srihari Veeraraghavan, MD
Pulmonary Disease · Atlanta, GANPI 1891704375
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 90.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $8,155 and has fallen 73.8% since, to $2,140 in 2024.
Across 28 payments — averaging $559.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$14K
- United Therapeutics Corporation$1K
- Genentech USA, Inc.$12
Across 383 payments — averaging $3399.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$802K
- United Therapeutics Corporation$345K
- Genentech, Inc.$54K
- E.r. Squibb & Sons, L.L.C.$47K
- Boehringer Ingelheim International GmbH$22K
- Biogen$17K
- plus $14K from 2 others
What the payments were for
- Consulting fees$8,61855%
- Speaking & faculty fees$4,52529%
- Travel & lodging$2,06613%
- Food & beverage$4353%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 22 | $14,160 |
| United Therapeutics Corporation | 5 | $1,496 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$11,144
How this compares
$15,668 in reported general payments places this provider in the 85th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 87 | $1,173,439 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $63,827 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $18,450 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $15,668 |
| Everolimus | 12 | $13,752 |
| Mycophenolate Mofetil | 103 | $13,474 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $12,936 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $9,795 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $7,949 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $7,417 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 171 | $5,425 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $5,100 |
| Mycophenolic AcidMycophenolate Sodium | 12 | $4,263 |
| Fluticasone Propionate HfaFluticasone Propionate | 14 | $3,655 |
| Ventolin HfaAlbuterol Sulfate | 24 | $1,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $14,160 | $1,173,43987 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Atlanta
- Colin SwensonAtlanta$255K
- Eric FlenaughAtlanta$93K
- Gregory MartinAtlanta$88K
- Victor TsengAtlanta$55K
- Ralitza MartinAtlanta$48K
- Venkatesh LakshminarayananAtlanta$33K
- Sisir AkkineniAtlanta$21K
- Gerald StatonAtlanta$21K
- Mirza AliAtlanta$16K
- Lawrence McDermottSavannah$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.